Trial Information
Current as of July 25, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
The study team conducted formative work to develop a new crisis response training for people involved in a law-enforcement assisted diversion program. The training, called Crisis Ready, combines an intervention that aims to promote use of 988 with a training on the use of Naloxone to reverse and overdose. The pilot aims to collect quantitative and qualitative data about the perceptions of the training among program participants and program staff.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Participates in the Baltimore Crisis Response, Inc Law Enforcement Assisted Diversion Program
- • Capacity to give informed consent
- Exclusion Criteria:
- • Unable to understand English
About Rand
RAND is a leading nonprofit research organization dedicated to improving policy and decision-making through rigorous analysis and evidence-based solutions. With a commitment to advancing public health, RAND conducts innovative clinical trials that aim to evaluate new treatments, interventions, and health policies. By leveraging multidisciplinary expertise and a collaborative approach, RAND strives to translate research findings into actionable insights that enhance healthcare outcomes and inform stakeholders across the medical and policy landscapes. Through its comprehensive studies, RAND plays a pivotal role in shaping the future of health and wellness on a global scale.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Baltimore, Maryland, United States
Patients applied
Trial Officials
Alison J Athey, PhD
Principal Investigator
RAND
Sapna Mendon-Plasek, PhD
Principal Investigator
RAND
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported